Seyed Parsa Eftekhar1, Sohrab Kazemi2, Mohammad Barary1, Mostafa Javanian3, Soheil Ebrahimpour3, Naghmeh Ziaei4. 1. Student Research Committee, Health Research Center, Babol University of Medical Sciences, Babol, Iran. 2. Cellular and Molecular Biology Research Center, Health Research Center, Babol University of Medical Sciences, Babol, Iran. 3. Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. 4. Department of Cardiology, Babol University of Medical Sciences, Babol, Iran.
Abstract
BACKGROUND: Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patients who received hydroxychloroquine with or without azithromycin. METHODS: This study was a retrospective cohort study. One hundred seventy-two confirmed COVID-19 patients were included in this study, hospitalized at Babol University of Medical Sciences hospitals between March 5, 2020, and April 3, 2020. Patients were divided into two groups: hydroxychloroquine alone and hydroxychloroquine with azithromycin. Electrocardiograms were used for outcome assessment. RESULTS: 83.1% of patients received hydroxychloroquine plus azithromycin vs. 16.9% of patients who received only hydroxychloroquine. The mean age of patients was 59.2 ± 15.4.The mean of posttreatment QTc interval in the monotherapy group was shorter than the mean of posttreatment QTc interval in the combination therapy group, but it had no significant statistical difference (462.5 ± 43.1 milliseconds vs. 464.3 ± 59.1 milliseconds; p = 0.488). Generally, 22.1% of patients had a prolonged QTc interval after treatment. Male gender, or baseline QTc ≥ 450 milliseconds, or high-risk Tisdale score increased the likelihood of prolonged QTc interval. Due to QTc prolongation, fourteen patients did not continue therapy after four days. CONCLUSIONS: Hospitalized patients treated by hydroxychloroquine with or without azithromycin had no significant difference in prolongation of QT interval and outcome. The numbers of patients with prolonged QT intervals in this study emphasize careful cardiac monitoring during therapy, especially in high-risk patients.
BACKGROUND: Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patients who received hydroxychloroquine with or without azithromycin. METHODS: This study was a retrospective cohort study. One hundred seventy-two confirmed COVID-19 patients were included in this study, hospitalized at Babol University of Medical Sciences hospitals between March 5, 2020, and April 3, 2020. Patients were divided into two groups: hydroxychloroquine alone and hydroxychloroquine with azithromycin. Electrocardiograms were used for outcome assessment. RESULTS: 83.1% of patients received hydroxychloroquine plus azithromycin vs. 16.9% of patients who received only hydroxychloroquine. The mean age of patients was 59.2 ± 15.4.The mean of posttreatment QTc interval in the monotherapy group was shorter than the mean of posttreatment QTc interval in the combination therapy group, but it had no significant statistical difference (462.5 ± 43.1 milliseconds vs. 464.3 ± 59.1 milliseconds; p = 0.488). Generally, 22.1% of patients had a prolonged QTc interval after treatment. Male gender, or baseline QTc ≥ 450 milliseconds, or high-risk Tisdale score increased the likelihood of prolonged QTc interval. Due to QTc prolongation, fourteen patients did not continue therapy after four days. CONCLUSIONS: Hospitalized patients treated by hydroxychloroquine with or without azithromycin had no significant difference in prolongation of QT interval and outcome. The numbers of patients with prolonged QT intervals in this study emphasize careful cardiac monitoring during therapy, especially in high-risk patients.
Authors: Moussa Saleh; James Gabriels; David Chang; Beom Soo Kim; Amtul Mansoor; Eitezaz Mahmood; Parth Makker; Haisam Ismail; Bruce Goldner; Jonathan Willner; Stuart Beldner; Raman Mitra; Roy John; Jason Chinitz; Nicholas Skipitaris; Stavros Mountantonakis; Laurence M Epstein Journal: Circ Arrhythm Electrophysiol Date: 2020-04-29
Authors: Nicholas J Mercuro; Christina F Yen; David J Shim; Timothy R Maher; Christopher M McCoy; Peter J Zimetbaum; Howard S Gold Journal: JAMA Cardiol Date: 2020-09-01 Impact factor: 14.676
Authors: Martin W Nicholson; Ching-Ying Huang; Jyun-Yuan Wang; Chien-Yu Ting; Yu-Che Cheng; Darien Z H Chan; Yi-Chan Lee; Ching-Chuan Hsu; Yu-Hung Hsu; Cindy M C Chang; Marvin L Hsieh; Yuan-Yuan Cheng; Yi-Ling Lin; Chien-Hsiun Chen; Ying-Ta Wu; Timothy A Hacker; Joseph C Wu; Timothy J Kamp; Patrick C H Hsieh Journal: Pharmaceuticals (Basel) Date: 2022-06-20
Authors: S Domingo-Echaburu; M Irazola; A Prieto; B Rocano; A Lopez de Torre-Querejazu; A Quintana; G Orive; U Lertxundi Journal: Sci Total Environ Date: 2022-01-19 Impact factor: 10.753